{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:48:53Z","timestamp":1773881333694,"version":"3.50.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T00:00:00Z","timestamp":1517529600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["NIRG-12- 92090"],"award-info":[{"award-number":["NIRG-12- 92090"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000957","name":"Alzheimer's Association","doi-asserted-by":"publisher","award":["NIRP-12-259245"],"award-info":[{"award-number":["NIRP-12-259245"]}],"id":[{"id":"10.13039\/100000957","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000026","name":"Institute of Aging","doi-asserted-by":"publisher","award":["MOP-11-51-31"],"award-info":[{"award-number":["MOP-11-51-31"]}],"id":[{"id":"10.13039\/501100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s00259-018-3933-3","type":"journal-article","created":{"date-parts":[[2018,2,2]],"date-time":"2018-02-02T12:52:48Z","timestamp":1517575968000},"page":"1021-1030","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer\u2019s disease"],"prefix":"10.1007","volume":"45","author":[{"name":"for the Alzheimer\u2019s Disease Neuroimaging Initiative","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tharick A.","family":"Pascoal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sulantha","family":"Mathotaarachchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Shin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ah Yeon","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Mohades","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea L.","family":"Benedet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min Su","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gassan","family":"Massarweh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Paul","family":"Soucy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serge","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Rosa-Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,2]]},"reference":[{"key":"3933_CR1","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.jalz.2016.02.002","volume":"12","author":"B Dubois","year":"2016","unstructured":"Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016;12:292\u2013323. https:\/\/doi.org\/10.1016\/j.jalz.2016.02.002 .","journal-title":"Alzheimers Dement"},{"key":"3933_CR2","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.neuron.2014.10.038","volume":"84","author":"R Sperling","year":"2014","unstructured":"Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimer's disease: implications for prevention trials. Neuron. 2014;84:608\u201322. https:\/\/doi.org\/10.1016\/j.neuron.2014.10.038 .","journal-title":"Neuron"},{"key":"3933_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0047739","volume":"7","author":"D Holland","year":"2012","unstructured":"Holland D, McEvoy LK, Desikan RS, Dale AM; Alzheimer's Disease Neuroimaging Initiative. Enrichment and stratification for predementia Alzheimer disease clinical trials. PLoS One. 2012;7:e47739. https:\/\/doi.org\/10.1371\/journal.pone.0047739 .","journal-title":"PLoS One"},{"key":"3933_CR4","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jalz.2015.12.003","volume":"12","author":"S Gauthier","year":"2016","unstructured":"Gauthier S, Albert M, Fox N, Goedert M, Kivipelto M, Mestre-Ferrandiz J, et al. Why has therapy development for dementia failed in the last two decades? Alzheimers Dement. 2016;12:60\u20134. https:\/\/doi.org\/10.1016\/j.jalz.2015.12.003 .","journal-title":"Alzheimers Dement"},{"key":"3933_CR5","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:280\u201392. https:\/\/doi.org\/10.1016\/j.jalz.2011.03.003 .","journal-title":"Alzheimers Dement"},{"key":"3933_CR6","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1093\/brain\/awp132","volume":"132","author":"M Fouquet","year":"2009","unstructured":"Fouquet M, Desgranges B, Landeau B, Duchesnay E, Mezenge F, de la Sayette V, et al. Longitudinal brain metabolic changes from amnestic mild cognitive impairment to Alzheimer's disease. Brain. 2009;132:2058\u201367. https:\/\/doi.org\/10.1093\/brain\/awp132 .","journal-title":"Brain"},{"key":"3933_CR7","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1212\/01.wnl.0000269790.05105.16","volume":"69","author":"W Jagust","year":"2007","unstructured":"Jagust W, Reed B, Mungas D, Ellis W, Decarli C. What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? Neurology. 2007;69:871\u20137. https:\/\/doi.org\/10.1212\/01.wnl.0000269790.05105.16 .","journal-title":"Neurology"},{"key":"3933_CR8","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s00259-017-3634-3","volume":"44","author":"N Torosyan","year":"2017","unstructured":"Torosyan N, Mason K, Dahlbom M, Silverman DHS; Alzheimer\u2019s Disease Neuroimaging Initiative. Value of FDG-PET scans of non-demented patients in predicting rates of future cognitive and functional decline. Eur J Nucl Med Mol Imaging. 2017;44:1355\u201363. https:\/\/doi.org\/10.1007\/s00259-017-3634-3 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3933_CR9","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1007\/s00259-017-3790-5","volume":"44","author":"S Morbelli","year":"2017","unstructured":"Morbelli S, Bauckneht M, Arnaldi D, Picco A, Pardini M, Brugnolo A, et al. 18F-FDG PET diagnostic and prognostic patterns do not overlap in Alzheimer's disease (AD) patients at the mild cognitive impairment (MCI) stage. Eur J Nucl Med Mol Imaging. 2017;44:2073\u201383; https:\/\/doi.org\/10.1007\/s00259-017-3790-5 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3933_CR10","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1212\/01.wnl.0000244749.20056.d4","volume":"68","author":"P Edison","year":"2007","unstructured":"Edison P, Archer HA, Hinz R, Hammers A, Pavese N, Tai YF, et al. Amyloid, hypometabolism, and cognition in Alzheimer disease: an [11C]PIB and [18F]FDG PET study. Neurology. 2007;68:501\u20138. https:\/\/doi.org\/10.1212\/01.wnl.0000244749.20056.d4 .","journal-title":"Neurology"},{"key":"3933_CR11","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1007\/s00259-013-2478-8","volume":"40","author":"A Bruck","year":"2013","unstructured":"Bruck A, Virta JR, Koivunen J, Koikkalainen J, Scheinin NM, Helenius H, et al. [11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment. Eur J Nucl Med Mol Imaging. 2013;40:1567\u201372. https:\/\/doi.org\/10.1007\/s00259-013-2478-8 .","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3933_CR12","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00401-010-0794-7","volume":"121","author":"C Duyckaerts","year":"2011","unstructured":"Duyckaerts C. Tau pathology in children and young adults: can you still be unconditionally baptist? Acta Neuropathol. 2011;121:145\u20137. https:\/\/doi.org\/10.1007\/s00401-010-0794-7 .","journal-title":"Acta Neuropathol"},{"key":"3933_CR13","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/mp.2016.37","volume":"22","author":"TA Pascoal","year":"2017","unstructured":"Pascoal TA, Mathotaarachchi S, Mohades S, Benedet AL, Chung CO, Shin M, et al. Amyloid-beta and hyperphosphorylated tau synergy drives metabolic decline in preclinical Alzheimer's disease. Mol Psychiatry. 2017;22:306\u201311. https:\/\/doi.org\/10.1038\/mp.2016.37 .","journal-title":"Mol Psychiatry"},{"key":"3933_CR14","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.jalz.2016.11.005","volume":"13","author":"TA Pascoal","year":"2017","unstructured":"Pascoal TA, Mathotaarachchi S, Shin M, Benedet AL, Mohades S, Wang S, et al. Synergistic interaction between amyloid and tau predicts the progression to dementia. Alzheimers Dement. 2017;13:644\u201353. https:\/\/doi.org\/10.1016\/j.jalz.2016.11.005 .","journal-title":"Alzheimers Dement"},{"key":"3933_CR15","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1007\/s00401-013-1151-4","volume":"126","author":"JB Toledo","year":"2013","unstructured":"Toledo JB, Xie SX, Trojanowski JQ, Shaw LM. Longitudinal change in CSF Tau and A\u03b2 biomarkers for up to 48 months in ADNI. Acta Neuropathol. 2013;126:659\u201370. https:\/\/doi.org\/10.1007\/s00401-013-1151-4 .","journal-title":"Acta Neuropathol"},{"key":"3933_CR16","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ana.21610","volume":"65","author":"LM Shaw","year":"2009","unstructured":"Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC, et al. Cerebrospinal fluid biomarker signature in Alzheimer's Disease Neuroimaging Initiative subjects. Ann Neurol. 2009;65:403\u201313. https:\/\/doi.org\/10.1002\/ana.21610 .","journal-title":"Ann Neurol"},{"key":"3933_CR17","doi-asserted-by":"publisher","first-page":"2362","DOI":"10.1016\/j.neuroimage.2011.09.012","volume":"59","author":"SF Eskildsen","year":"2012","unstructured":"Eskildsen SF, Coupe P, Fonov V, Manjon JV, Leung KK, Guizard N, et al. BEaST: brain extraction based on nonlocal segmentation technique. Neuroimage. 2012;59:2362\u201373. https:\/\/doi.org\/10.1016\/j.neuroimage.2011.09.012 .","journal-title":"Neuroimage"},{"key":"3933_CR18","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1109\/TMI.2002.806283","volume":"21","author":"AP Zijdenbos","year":"2002","unstructured":"Zijdenbos AP, Forghani R, Evans AC. Automatic \"pipeline\" analysis of 3-D MRI data for clinical trials: application to multiple sclerosis. IEEE Trans Med Imaging. 2002;21:1280\u201391. https:\/\/doi.org\/10.1109\/TMI.2002.806283 .","journal-title":"IEEE Trans Med Imaging"},{"key":"3933_CR19","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/ana.23650","volume":"72","author":"SM Landau","year":"2012","unstructured":"Landau SM, Mintun MA, Joshi AD, Koeppe RA, Petersen RC, Aisen PS, et al. Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol. 2012;72:578\u201386. https:\/\/doi.org\/10.1002\/ana.23650 .","journal-title":"Ann Neurol"},{"key":"3933_CR20","doi-asserted-by":"publisher","first-page":"378","DOI":"10.2967\/jnumed.111.090340","volume":"53","author":"AD Joshi","year":"2012","unstructured":"Joshi AD, Pontecorvo MJ, Clark CM, Carpenter AP, Jennings DL, Sadowsky CH, et al. Performance characteristics of amyloid PET with florbetapir F18 in patients with Alzheimer's disease and cognitively normal subjects. J Nucl Med. 2012;53:378\u201384. https:\/\/doi.org\/10.2967\/jnumed.111.090340 .","journal-title":"J Nucl Med"},{"key":"3933_CR21","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1098\/rstb.2001.0915","volume":"356","author":"J Mazziotta","year":"2001","unstructured":"Mazziotta J, Toga A, Evans A, Fox P, Lancaster J, Zilles K, et al. A probabilistic atlas and reference system for the human brain: international consortium for brain mapping (ICBM). Philos Trans R Soc Lond B Biol Sci. 2001;356:1293\u2013322. https:\/\/doi.org\/10.1098\/rstb.2001.0915 .","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"3933_CR22","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack Jr","year":"2013","unstructured":"Jack CR Jr, Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12:207\u201316. https:\/\/doi.org\/10.1016\/S1474-4422(12)70291-0 .","journal-title":"Lancet Neurol"},{"key":"3933_CR23","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fninf.2016.00020","volume":"10","author":"S Mathotaarachchi","year":"2016","unstructured":"Mathotaarachchi S, Wang S, Shin M, Pascoal TA, Benedet AL, Kang MS, et al. VoxelStats: a MATLAB package for multi-modal voxel-wise brain image analysis. Front Neuroinform. 2016;10:20. https:\/\/doi.org\/10.3389\/fninf.2016.00020 .","journal-title":"Front Neuroinform"},{"key":"3933_CR24","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.neuroimage.2009.12.059","volume":"50","author":"KK Leung","year":"2010","unstructured":"Leung KK, Clarkson MJ, Bartlett JW, Clegg S, Jack CR Jr, Weiner MW, et al. Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: tissue-specific intensity normalization and parameter selection. Neuroimage. 2010;50:516\u201323. https:\/\/doi.org\/10.1016\/j.neuroimage.2009.12.059 .","journal-title":"Neuroimage"},{"key":"3933_CR25","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.neurobiolaging.2012.03.006","volume":"34","author":"JD Grill","year":"2013","unstructured":"Grill JD, Di L, Lu PH, Lee C, Ringman J, Apostolova LG, et al. Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's disease Neuroimaging initiative. Neurobiol Aging. 2013;34:62\u201372. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2012.03.006 .","journal-title":"Neurobiol Aging"},{"key":"3933_CR26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol. 1995;57:289\u2013300.","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"3933_CR27","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1001\/archneur.57.3.339","volume":"57","author":"NC Fox","year":"2000","unstructured":"Fox NC, Cousens S, Scahill R, Harvey RJ, Rossor MN. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. Arch Neurol. 2000;57:339\u201344.","journal-title":"Arch Neurol"},{"key":"3933_CR28","doi-asserted-by":"publisher","unstructured":"Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, Madison C, Ayakta N, Ghosh PM, et al. Existing Pittsburgh compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain. 2015;138:2020\u201333. https:\/\/doi.org\/10.1093\/brain\/awv112 .","DOI":"10.1093\/brain\/awv112"},{"issue":"Suppl","key":"3933_CR29","doi-asserted-by":"publisher","first-page":"S133","DOI":"10.1002\/ana.410150726","volume":"15","author":"DE Kuhl","year":"1984","unstructured":"Kuhl DE, Metter EJ, Riege WH, Hawkins RA. The effect of normal aging on patterns of local cerebral glucose utilization. Ann Neurol. 1984;15(Suppl):S133\u20137.","journal-title":"Ann Neurol"},{"key":"3933_CR30","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1097\/00004647-199605000-00005","volume":"16","author":"JR Moeller","year":"1996","unstructured":"Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Mandel F, Alexander GE, et al. The metabolic topography of normal aging. J Cereb Blood Flow Metab. 1996;16:385\u201398. https:\/\/doi.org\/10.1097\/00004647-199605000-00005 .","journal-title":"J Cereb Blood Flow Metab"},{"key":"3933_CR31","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1212\/WNL.0000000000000467","volume":"82","author":"VJ Lowe","year":"2014","unstructured":"Lowe VJ, Weigand SD, Senjem ML, Vemuri P, Jordan L, Kantarci K, et al. Association of hypometabolism and amyloid levels in aging, normal subjects. Neurology. 2014;82:1959\u201367. https:\/\/doi.org\/10.1212\/WNL.0000000000000467 .","journal-title":"Neurology"},{"key":"3933_CR32","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1212\/01.wnl.0000333247.51383.43","volume":"72","author":"L Mosconi","year":"2009","unstructured":"Mosconi L, Mistur R, Switalski R, Brys M, Glodzik L, Rich K, et al. Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease. Neurology. 2009;72:513\u201320. https:\/\/doi.org\/10.1212\/01.wnl.0000333247.51383.43 .","journal-title":"Neurology"},{"key":"3933_CR33","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1212\/WNL.58.12.1791","volume":"58","author":"DR Thal","year":"2002","unstructured":"Thal DR, Rub U, Orantes M, Braak H. Phases of a beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791\u2013800.","journal-title":"Neurology"},{"key":"3933_CR34","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1212\/WNL.52.6.1158","volume":"52","author":"A Delacourte","year":"1999","unstructured":"Delacourte A, David JP, Sergeant N, Buee L, Wattez A, Vermersch P, et al. The biochemical pathway of neurofibrillary degeneration in aging and Alzheimer's disease. Neurology. 1999;52:1158\u201365.","journal-title":"Neurology"},{"key":"3933_CR35","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 1991;82:239\u201359.","journal-title":"Acta Neuropathol"},{"key":"3933_CR36","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/brain\/awu367","volume":"138","author":"N Mattsson","year":"2015","unstructured":"Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, Shaw LM, et al. Independent information from cerebrospinal fluid amyloid-beta and florbetapir imaging in Alzheimer's disease. Brain. 2015;138:772\u201383. https:\/\/doi.org\/10.1093\/brain\/awu367 .","journal-title":"Brain"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-018-3933-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-018-3933-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-018-3933-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T22:53:36Z","timestamp":1719788016000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-018-3933-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,2]]},"references-count":36,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["3933"],"URL":"https:\/\/doi.org\/10.1007\/s00259-018-3933-3","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,2]]},"assertion":[{"value":"12 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Serge Gauthier received honoraria for serving on the scientific advisory boards of Alzheon, Axovant, Lilly, Lundbeck, Novartis, Schwabe, TauRx, on the Data Safety Monitoring Board of a study sponsored by Eisai, and studies run by the Alzheimer's Disease Cooperative Study and by the Alzheimer's Therapeutic Research Institute. All the other authors declare no conflicts of interest.Gassan Massarweh declares that he has no conflict of interest","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}